Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients
Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who had EGFR-mutant non-small cell lung cancer (NSCLC) that had developed resistance ...
Mar 31, 2019
0
1